Sitagliptin in Recurrent/Progressive Grade 4 Glioma

In this Phase I trial, it is proposed that sitagliptin will be used to inhibit Myeloid Derived Suppressor Cells (MDSCs) in recurrent Glioblastoma (GBM). As this trial designed is for patients with recurrent GBM, patients will receive standard of care, bevacizumab, in addition to sitagliptin. The goal of this trial is to provide the proof of concept that suppressing MDSCs via sitagliptin is safe and feasible in patients with recurrent GBMs.

In the Phase Ib component, a standard 3+3 design and dose de-escalation will be used to determine the maximal tolerated dose (MTD) of sitagliptin in combination with bevacizumab in non-surgical patients with recurrent GBM.

After completion of the Phase Ib part, the study will proceed to the pilot phase. In the pilot phase component, 12 patients with recurrent GBM, who will receive pre-operative treatment with sitagliptin for at least 5 days at the MTD determined in phase 1b, will be enrolled. These patients will then undergo surgical resection of the tumor. All patients will receive postoperative sitagliptin in addition to standard-of-care bevacizumab. Tumor tissue will undergo dissociation and single-cell sequencing, immune profiling, and whole genome sequencing. The goal of the pilot phase is to obtain preliminary evidence demonstrating a reduction in the concentration of circulating MDSCs after the treatment of sitagliptin and to provide preliminary evidence of sitagliptin in reducing infiltrating MDSCs in the GBM tumor microenvironment. Patients will have their steroid dosing reduced to the equivalence of 4 mg dexamethasone per day or lower for at least 5 days prior to preoperative sitagliptin.

Inclusion criteria

Phase 1b

• Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy is diagnosed by the treating physician.
• Subjects must not have received sitagliptin or bevacizumab for this disease.
• Age >18 years
• Performance status: ECOG performance status 0-2
• Subjects must have adequate organ function and laboratory parameters within 21 days of study entry as defined below:

• Hemoglobin ≥ 9 g/dl
• Absolute neutrophil count ≥ 1,500/mcL
• Platelet count ≥ 100,000/mcL
• Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
• AST (SGOT) ≤ 3 X institutional ULN
• ALT (SGPT) ≤ 3 X institutional ULN
• Calculated creatinine clearance > 50 mL/min
• Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio.

For UPC ratio > 0.5, 24-hour urine protein must be obtained and must be < 1000 mg.

• Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:

• No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
• In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
• Subjects must have the ability to understand and the willingness to sign a written informed consent document.
• Women of childbearing potential, defined as any female who has experienced menarche and has not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy) and is not postmenopausal (≥12 months of spontaneous amenorrhea without an alternative medical cause), must have a negative pregnancy test within 7 days prior to treatment start. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.
• Subjects must be able to swallow whole tablets.
• Participants must have controlled blood pressure, defined as systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 100 mg Hg, with or without antihypertensive therapy
• Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior study treatment
• Subjects must have the following minimum intervals from prior treatments until planned treatment initiation of Cycle 1 Day 1:

• surgery - 4 weeks
• nitrosoureas - 6 weeks
• cytotoxic chemotherapy - standard intervals depending on the most recent regimen. i.e., for temozolomide 5 of 28, 23 days after most recent temozolomide; for temozolomide 21 of 28 days, 7 days after most recent dose; etoposide 14 of 21 days, 7 days after last dose.
• For drugs not listed, the research nurse, treating investigator, and principal investigator will determine the appropriate interval.
• Investigational therapy or non-cytotoxic GBM related therapy - 2 weeks
• Subject is not deemed as a surgical candidate.

Pilot Phase

• Subjects must have histologically or cytologically confirmed WHO grade 4 glioma for which disease recurrence/progression after first line therapy is diagnosed by the treating physician.
• Subjects must not have received sitagliptin or bevacizumab for this disease.
• Age >18 years
• Performance status: ECOG performance status 0-2
• Subjects must have adequate organ function and laboratory parameters within 21 days of study entry as defined below:

• Hemoglobin ≥ 9 g/dl
• Absolute neutrophil count ≥ 1,500/mcL
• Platelet count ≥ 100,000/mcL
• Total bilirubin < 1.5 x institutional upper limit of normal (ULN)
• AST (SGOT) ≤ 3 X institutional ULN Version date: 30March2026 Page 16
• ALT (SGPT) ≤ 3 X institutional ULN
• Calculated creatinine clearance > 50 mL/min
• Urine protein screened by urine analysis for urine protein creatinine (UPC) ratio.

For UPC ratio > 0.5, 24-hour urine protein must be obtained and must be < 1000 mg.

• Patients on full-dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:

• No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
• In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin
• Subjects must have the ability to understand and the willingness to sign a written informed consent document.
• Women of childbearing potential, defined as any female who has experienced menarche and has not undergone surgical sterilization (e.g., hysterectomy, bilateral oophorectomy) and is not postmenopausal (≥12 months of spontaneous amenorrhea without an alternative medical cause), must have a negative pregnancy test within 7 days of treatment start. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and through 30 days after the last dose of study drug. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and through 30 days after the last dose of study drug.
• Subjects must be able to swallow whole tablets.
• Subjects must have controlled blood pressure, defined as systolic blood pressure ≤ 160 mg Hg or diastolic pressure ≤ 100 mg Hg, with or without antihypertensive therapy
• Electrocardiogram without evidence of acute cardiac ischemia within 14 days prior to treatment start
• Subjects must have the following minimum intervals from prior treatments until planned treatment initiation of Cycle 1Day1:

• surgery - 4 weeks
• nitrosoureas - 6 weeks
• cytotoxic chemotherapy - standard intervals depending on the most recent regimen. i.e., for temozolomide 5 of 28, 23 days after most recent temozolomide; for temozolomide 21 of 28 days, 7 days after most recent dose; etoposide 14 of 21 days, 7 days after last dose.
• For drugs not listed, the research nurse, treating investigator, and principal investigator will determine the appropriate interval.
• Investigational therapy or GBM related non-cytotoxic therapy - 2 weeks
• For bevacizumab (if for a different cancer) - 4 weeks from the expected date of protocol surgery
• Subject is deemed as a surgical candidate.

Exclusion criteria

(for phase 1b and pilot phase)

• Prior treatment toxicities not resolved to ≤ Grade 1 according to NCI CTCAE Version 5.0 except for alopecia and neuropathy.
• Subjects receiving any other investigational agents.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to sitagliptin or bevacizumab.
• Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Known HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with sitagliptin and/or bevacizumab. In addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy.
• Other malignancy within the past 2 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or vulva; c) prostate cancer of Gleason Score 6 or less with stable prostate specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder, or benign tumors of the adrenal or pancreas.
• Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 5.0 [CTCAE v.5.0] diarrhea of any etiology at screening).
• Known active infection with hepatitis B or hepatitis C virus.
• Pregnant or breastfeeding.
• Subjects who receive insulin or sulfonylurea for diabetes mellitus.
• Subjects with history of type 1 diabetes, uncontrolled type 2 diabetes, hypoglycemia requiring medical intervention, or those who are deemed not suitable to receive sitagliptin at the discretion of the investigators.
• Unable or unwilling to swallow tablets.
• Evidence of significant medical illness, abnormal laboratory finding, or psychiatric illness/social situations that would, in the Investigator's judgment, make the patient inappropriate for this study.
• Arterial ischemic event (e.g., unstable angina, myocardial infarction, stroke) within 6 months of study consent.
• Subjects with history of hematologic bleeding disorder.